Climb Bio (CLYM) Preferred Stock Liabilities (2020 - 2021)
Climb Bio (CLYM) posted Preferred Stock Liabilities of $152.8 million for Q2 2021, up 64.61% on a QoQ basis from $92.8 million in Q1 2021, and up 464.42% year-over-year from $27.1 million in Q2 2020.
Climb Bio (CLYM) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Climb Bio's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $152.8 million for Q2 2021.
- Quarterly Preferred Stock Liabilities rose 464.42% year-over-year to $152.8 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $152.8 million (up 464.42% YoY) and the FY2020 annual result came in at $46.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $152.8 million for Q2 2021 at Climb Bio, up from $92.8 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $152.8 million in Q2 2021 and bottomed at $27.1 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Climb Bio | 870.33 Mn | 870.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 152.76 Mn |
| Mar 31, 2021 | 92.80 Mn |
| Dec 31, 2020 | 46.55 Mn |
| Sep 30, 2020 | 27.53 Mn |
| Jun 30, 2020 | 27.07 Mn |